Michael B. Atkins

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile

0.123Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Real-world outcomes of treatment with immune checkpoint inhibitors in unique patient cohorts: Elderly, non-caucasian race, poor performance status, obese, chronic viral infections, and autoimmune diseases.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2641

Top 71%

0.123DataRank

Top 71%1 citations

Shuo Wang, Aquino Williams, Melinda S. Weber, Brittany Sinclaire, Elli Gourna Paleoudis +14 more

Papers

Driven by 43 papers — median percentile 14. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology(2022)10.1200/jco.22.01763

N/A

5.4DataRank · unranked

446 citations

Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach‐Giao Truong +31 more

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Neuro-Oncology(2021)10.1093/neuonc/noab094

N/A

4.0DataRank · unranked

126 citations

Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid +18 more

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

Pigment Cell & Melanoma Research(2020)10.1111/pcmr.12861

N/A

1.6DataRank · unranked

57 citations

Keiran S.M. Smalley, Priscilla K. Brastianos, Michael A. Davies, Ian E. McCutcheon, James K. Liu +13 more

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

New England Journal of Medicine(2018)10.1056/nejmoa1805453

N/A

1.1DataRank · unranked

1335 citations

Peter A. Forsyth, Alain Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos +17 more

Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.03.019

N/A

0.848DataRank · unranked

20 citations

Michael B. Atkins, Toni K. Choueiri, Despina Thomaidou, Brad Rosbrook, M. Thakur +2 more

Dissecting the treatment-naive ecosystem of human melanoma brain metastasis

Cell(2022)10.1016/j.cell.2022.06.007

N/A

0.807DataRank · unranked

216 citations

Johannes C. Melms, Amit Dipak Amin, Yiping Wang, Lindsay Caprio, Alcida Karz +54 more

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma

Nature Communications(2021)10.1038/s41467-021-21068-9

N/A

0.770DataRank · unranked

169 citations

David A. Braun, Sachet A. Shukla, Wenting Pan, Xīn Gào, Yue Hou +48 more

Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials

Nephrology Dialysis Transplantation(2022)10.1093/ndt/gfac342

N/A

0.767DataRank · unranked

11 citations

Finnian R. Mc Causland, Brian Claggett, Christoph Wanner, Andrzej Więcek, Michael B. Atkins +13 more

The State of Melanoma: Emergent Challenges and Opportunities

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4092

N/A

0.705DataRank · unranked

109 citations

Clara Curiel‐Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre‐Ghiso +31 more

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009495

N/A

0.615DataRank · unranked

19 citations

Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir +13 more

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2283

N/A

0.609DataRank · unranked

57 citations

Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer +16 more

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5023

N/A

0.599DataRank · unranked

12 citations

Opeyemi A. Jegede, Miriam Sant’Angelo, Sonia Moreno, David A. Braun, Megan Wind‐Rotolo +15 more

Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa064

N/A

0.557DataRank · unranked

40 citations

Michael B. Atkins, Ziad Bakouny, Maria I. Carlo, Charles G. Drake, Eric Jonasch +15 more

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-003743

N/A

0.542DataRank · unranked

36 citations

Charlene Mantia, Lillian Werner, Ahmad A. Tarhini, James Larkin, F. Stephen Hodi +10 more

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

Pigment Cell & Melanoma Research(2022)10.1111/pcmr.13059

N/A

0.425DataRank · unranked

16 citations

Maya Dimitrova, Kevin Kleffman, Christopher Alvarez‐Breckenridge, Michael B. Atkins, Adrienne Boire +22 more

Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials

Cancer Epidemiology Biomarkers & Prevention(2023)10.1158/1055-9965.epi-23-0420

N/A

0.345DataRank · unranked

9 citations

Ju‐Whei Lee, Angela Wangari Walter, Rachel Rosen, Ilana F. Gareen, Sheetal Mehta Kircher +17 more

A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma

The Oncologist(2024)10.1093/oncolo/oyad298

N/A

0.269DataRank · unranked

5 citations

Katharina Leucht, Wanling Xie, Opeyemi Jegede, David A Braun, Michael B. Atkins +3 more

Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12134

N/A

0.208DataRank · unranked

3 citations

Jacob P. Zaemes, Jaeil Ahn, L.C. Fernando Pascual, Brittany Sinclaire, Shaked Lev‐Ari +9 more

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.28.121806

N/A

0.208DataRank · unranked

3 citations

David A. Braun, Sachet A. Shukla, Wenting Pan, Xīn Gào, Yue Hou +47 more

Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6514

N/A

0.189DataRank · unranked

2 citations

Ju‐Whei Lee, Ilana F. Gareen, Sheetal Kircher, B. Herman, Joanna M. Streck +14 more

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9559

N/A

0.165DataRank · unranked

2 citations

Yue Zheng, Michael B. Atkins, Bartosz Chmielowski, Ahmad A. Tarhini, Thach‐Giao Truong +14 more

Real-world outcomes of treatment with immune checkpoint inhibitors in unique patient cohorts: Elderly, non-caucasian race, poor performance status, obese, chronic viral infections, and autoimmune diseases.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2641

Top 71%

0.123DataRank

Top 71%1 citations

Shuo Wang, Aquino Williams, Melinda S. Weber, Brittany Sinclaire, Elli Gourna Paleoudis +14 more

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.100947

N/A

0DataRank · unranked

27 citations

Evan J. Lipson, Ludmila Danilova, Suzanne L. Topalian, Jaroslaw Jedrych, Ezra Baraban +10 more

Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice

Gastroenterology(2020)10.1053/j.gastro.2020.11.044

N/A

0DataRank · unranked

92 citations

Sivanesan Dakshanamurthy, Matthew McCoy, Anastasia Mavropoulos, Bedilu Allo, Aimy Sebastian +14 more

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.604

N/A

0DataRank · unranked

5 citations

Opeyemi A. Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asım Bilen, Mark N. Stein +11 more

Data from Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response

(2023)10.1158/0008-5472.c.6513106.v1

N/A

0DataRank · unranked

0 citations

Juntae Kwon, Min Soon Cho, Yifan Sun, Xiaofeng Zheng, Jing Wang +6 more

Supplementary Figure 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2023)10.1158/2326-6066.22537789

N/A

0DataRank · unranked

0 citations

Donald P. Lawrence, Cecilia Lezcano, Xinqi Wu, Jun Zhou, Tetsuro Sasada +18 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Annals of Oncology(2024)10.1016/j.annonc.2024.07.727

N/A

0DataRank · unranked

198 citations

Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008293

N/A

0DataRank · unranked

6 citations

Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein +11 more

Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials

Journal of Pain and Symptom Management(2024)10.1016/j.jpainsymman.2024.12.021

N/A

0DataRank · unranked

2 citations

Ju‐Whei Lee, Ilana F. Gareen, Sheetal Mehta Kircher, Shaji Kumar, Ingrid A. Mayer +10 more

Effects of a Tailored Mobile Messaging Intervention for Indoor Tanning Cessation in Young Females: A Randomized Clinical Trial

Cancer Epidemiology Biomarkers & Prevention(2024)10.1158/1055-9965.epi-24-0964

N/A

0DataRank · unranked

1 citations

Mahmood A. Alalwan, Lauren Long, Michael B. Atkins, Kenneth P. Tercyak, Darren Mays

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

Cancer Discovery(2025)10.1158/2159-8290.cd-24-0991

N/A

0DataRank · unranked

38 citations

Lena V. Wirth, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.27.661875

N/A

0DataRank · unranked

0 citations

Sumeet Patiyal, Lipika R. Pal, Tiangen Chang, Sumona Biswas, Saugato Rahman Dhruba +36 more

Utilizing Immuno-Oncology registry data for enhanced non-small cell lung cancer treatment predictions

JAMIA Open(2025)10.1093/jamiaopen/ooaf069

Top 100%

0DataRank

Top 100%0 citations

Shaked Lev‐Ari, Jacob P. Zaemes, Alexandra Della Pia, Bianca DeAgresta, Samir Gupta +13 more

The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG‐ACRIN Cancer Research Group trials

UNC Libraries(2025)10.17615/c1xc-d466

N/A

0DataRank · unranked

0 citations

Ju‐Whei Lee, Sheetal Mehta Kircher, Lynne I. Wagner, Frank S. Hodi, Jamie S. Ostroff +16 more

Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1362

N/A

0DataRank · unranked

0 citations

Miya B. Hugaboom, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma

Radiology(2020)10.1148/radiol.2020201763

N/A

0DataRank · unranked

16 citations

Rupal S. Bhatt, Meaghan F. Strob, Opeyemi A. Jegede, Maryellen Sun, David C. Alsop +6 more

Late immune-related adverse events with immune checkpoint inhibitors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2635

N/A

0DataRank · unranked

1 citations

Shuo Wang, Divya Cheruku, Kanchi Krishnamurthy, Melinda S. Weber, Brittany Sinclaire +15 more

A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps9591

N/A

0DataRank · unranked

4 citations

Sandra J. Lee, Michael B. Atkins, Terence Z. Wong, Jennifer L. Guerriero, Thomas U. Marron +8 more

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.36_suppl.356154

N/A

0DataRank · unranked

111 citations

Sandra J. Lee, Bartosz Chmielowski, Antoni Ribas, Ahmad A. Tarhini, Thach‐Giao Truong +9 more

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2274

N/A

0DataRank · unranked

37 citations

Opeyemi A. Jegede, Sayed Matar, Nourhan El Ahmar, Destiny J. West, Emily Walton +16 more

Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

npj Precision Oncology(2023)10.1038/s41698-023-00471-z

N/A

0DataRank · unranked

24 citations

Jennifer R. Ribeiro, Jun Yin, Joanne Xiu, Matías A. Bustos, Fumito Ito +17 more

Michael B. Atkins

Indexed papers

Top data-sharing exemplar

Papers